Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery

Summary

The aim of this study is to evaluate the feasibility of randomizing individuals to low molecular weight heparin (enoxaparin) or no treatment following cesarean delivery. The investigators hypothesize that among eligible individuals, at least 35% will enroll, undergo randomization, and complete the allocated treatment group.

Timeline

Start

2023-10-11

Primary completion

2024-07-01

Completion

2024-07-01

Drugs

Indications